Statement | 17 November 2014 Research and development R&D cost estimates - MSF response to Tufts CSDD study on cost to develop a new drug
Statement | 03 November 2014 Hepatitis C Intellectual property and trade MSF responds to BMS commercial strategy for hepatitis C drug daclatasvir in developing countries 5 min
Statement | 16 October 2014 Intellectual property and trade MSF responds to second Wikileaks release of Trans-Pacific Partnership text 3 min
Statement | 16 October 2014 Research and development Vaccines MSF responds to GSK remarks on Ebola vaccine
Statement | 10 October 2014 Hepatitis C MSF responds to USFDA approval of first combination hepatitis C treatment 3 min
Statement | 01 October 2014 Intellectual property and trade Regulatory System Strengthening: MSF intervention at 67th WHA
Statement | 14 September 2014 Hepatitis C India MSF Access Campaign response to Gilead’s deal with generic companies for sofosbuvir and ledipasvir 6 min
